Pindolol
Beta Blocking Agents, Non-Selective
Sold as VISKEN · VISKAZIDE
- Drug class
- Beta Blocking Agents, Non-Selective
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 5
- FDA reports (12 mo)
- 20
Overview
Plain-language summary, compiled from the cited regulatory records
Pindolol is a medication classified as a non-selective beta-blocking agent [1]. It is approved for the management of high blood pressure (hypertension) [1]. Pindolol can be used as a standalone treatment or in combination with other medications that lower blood pressure, such as diuretics of the thiazide type [1].
In the past 12 months, there have been 20 adverse event reports associated with pindolol [2]. Among the reported adverse events, the most frequent included difficulty breathing (dyspnoea), abnormal hemoglobin levels, hereditary angioedema, abnormal neutrophil counts, and inflammation of the esophagus (esophagitis) [2].
This medication is available under various brand names.
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 3 | March 22, 2025 |
| US United States | FDA | 1 | October 9, 2025 |
| GB United Kingdom | MHRA | 1 | April 10, 2026 |
CACanada· Health Canada
3 products
Uses
Hypertension TEVA-PINDOLOL (pindolol) is indicated for the treatment of mild to moderate hypertension. Pindolol is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be used alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a β-blocker rather than a diuretic.
The combination of pindolol with a diuretic and/or peripheral vasodilator has been found to be compatible and generally more effective than pindolol alone. Limited experience with other antihypertensive agents, including methyldopa, has not shown evidence of incompatibility with pindolol.
TEVA-PINDOLOL is not recommended for the emergency treatment of hypertensive crises. Angina Pectoris TEVA-PINDOLOL is indicated for the prophylaxis (prevention) of angina pectoris. CONTRAINDICATIONS TEVA-PINDOLOL (pindolol) is contraindicated in: Patients who are hypersensitive to this drug or to any ingredient in the formulation.
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.
How to take
GBUnited Kingdom· MHRA
1 product
Uses
This medicine is indicated in adults for the treatment of essential hypertension. It is also used as a prophylactic treatment of angina pectoris.
How to take
Drug interactions
Known interactions involving Pindolol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 437. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 00869007 · revised March 22, 2025
- [2]FDA DailyMed · 0daed7b3-6017-46… · revised October 9, 2025 [PDF]
- [3]MHRA (UK) · PL200720021 · revised April 10, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.